PCI startup ŌNŌCOR has announced the first-in-human use of their ŌNŌ endovascular retrieval system for the removal of an intracardiac tumor. Intracardiac tumors (abnormal growth of tissues inside the heart) affect thousands of patients around the world annually, but prior to ŌNŌ, open-heart surgery was the only way to remove them.
Using the ŌNŌ system in combination with electrocautery, a procedure that uses heat from an electric current to destroy abnormal tissue, Dr. James M. McCabe and Dr. Zachary L. Steinberg and their team at the University of Washington Medical Center were able to remove an intracardiac tumor from a 54-year-old patient. This first-of-its-kind procedure opens the door to a new therapeutic strategy for patients around the world, as it allows doctors to remove intracardiac tumors without performing high-risk open heart surgery.
The ŌNŌ system is a novel device designed to receive, align, compress, and remove material from the vascular system. ŌNŌ received FDA clearance in May 2022 and is available at select sites throughout the United States.
“We are thrilled that ŌNŌ was able to facilitate the innovative work of Drs. McCabe and Steinberg at UW,” said Mark Piper, CEO of ŌNŌCOR. “We’ve always believed that ŌNŌ would be a tool that helps physicians safely expand the scope of minimally invasive procedures. I think that what we witnessed here today in Seattle is a clear example of how new technologies such as ŌNŌ potentiate the evolution of medical therapy.”
To learn more about ŌNŌCOR and ŌNŌ, read here.
